Q-omics provides the consensus-scored RPS3A profile across patient tissues and cancer cell-line models. RPS3A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RPS3A is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPS3A protein abundance shows 29,695 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, KIRC, and GBM as cancer lineages where RPS3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS3A survival associations across molecular data types. RPS3A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS3A RNA expression–survival associations across cancer types. High RPS3A expression shows unfavorable associations in ACC, LIHC, SCLC and CESC, but favorable associations in BRCA and LGG. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for RPS3A RNA expression.
This table summarizes RPS3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RPS3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS3A shows lower tumor expression in BLCA, HNSC, UCEC and BRCA and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher RPS3A RNA expression in tumor versus normal tissue (log2 FC = +0.493, t-test p < 0.001).
This table shows molecular features associated with RPS3A in patient tissues and cancer cell lines. In patient samples, RPS3A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
